⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29025153 | 0.77 | — | — | |
| SCHEMBL7609085 | 0.76 | ERN1 (0.38) | — | |
| SCHEMBL986987 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL5745528 | 0.73 | — | — | |
| SCHEMBL1094456 | 0.73 | — | — | |
| SCHEMBL24766044 | 0.73 | — | — | |
| SCHEMBL29953193 | 0.73 | — | — | |
| SCHEMBL613748 | 0.73 | — | — | |
| SCHEMBL5700538 | 0.73 | — | — | |
| SCHEMBL457223 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021013419-A1 | INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL | HENKEL AG & CO. KGAA (DE) | 2021-01-28 | — | — | WO | claimed |
| CN-112689637-B | Imidazopyridone compounds | 橘生药品工业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-109912662-B | Solution-processable dendritic iridium complex electroluminescent material and synthesis method thereof | 东南大学 | 2021-10-19 | — | — | CN | disclosed |
| US-20210206765-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-08 | — | — | US | disclosed |
| EP-3808747-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-04-21 | — | — | EP | disclosed |
| CN-112689637-A | Imidazopyridinone compounds | 橘生药品工业株式会社 | 2021-04-20 | — | — | CN | disclosed |
| EP-3157909-B1 | LMP7 INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-04-07 | — | — | EP | disclosed |
| WO-2021013419-A1 | INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL | HENKEL AG & CO. KGAA (DE) | 2021-01-28 | — | — | WO | disclosed |
| US-20180208589-A1 | LMP7 INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-07-26 | — | — | US | disclosed |
| CN-108286186-A | A kind of new type low temperature oxygen bleaching catalyst and its preparation method and application | 上海雅运纺织助剂有限公司 | 2018-07-17 | — | — | CN | disclosed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-3157909-A1 | LMP7 INHIBITORS | Principia Biopharma Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015195950-A1 | LMP7 INHIBITORS | PRINCIPIA BIOPHAMRAM INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20140335019-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140335019-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-11-13 | — | — | US | disclosed |
| WO-2013082508-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND ANALYSIS OF NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-06 | — | — | WO | disclosed |